"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss." Diabetes, Obesity and Metabolism
NS has consulted for Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Hanmi Pharmaceuticals, Janssen, MSD, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, Sanofi and received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics
An N, Zhang G, Li Y, Yuan C, Yang F, Zhang L, et al
Lets look at the possible reasons behind this reaction
Ozempic has only been on the market since 2017, whereas Wegovy was approved for weight loss in 2021